# PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites

> **NCT05501340** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital of Soochow University** · enrollment: 40 (estimated)

## Conditions studied

- Malignant Ascites

## Interventions

- **DRUG:** Serplulimab
- **DRUG:** Molgramostim
- **RADIATION:** Hypofractionated radiotherapy/Sterotactic body radiotherapy

## Key facts

- **NCT ID:** NCT05501340
- **Lead sponsor:** Second Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2024-09-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05501340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05501340, "PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05501340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*